Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)

University of Calgary

$100,000.00

TOP1MT, mtDNA Release & Inflammation

EF 2022-23

Résumé
Mitochondria, best known as the powerhouse of the cell, contain a small DNA genome, known as mtDNA that is essential for mitochondrial function. Recent work shows that when mtDNA escapes from mitochondria, it can activate immune signaling. While immune signaling can be protective in the context of infections, excess activation can be detrimental by leading to autoimmune disorders. The triggers initiating mtDNA escape and the mechanisms by which mtDNA exits mitochondria are not fully understood. We also do not have a full appreciation of the consequences of mtDNA release on human health. To begin to answer these questions, we will study the mtDNA regulator TOP1MT, which our novel findings show mediates mtDNA escape. With respect to human health, we have identified a candidate disease causing TOP1MT variant in a family with autoimmune disorders, and shown that this variant is linked to mtDNA release and immune activation. These findings support a role for TOP1MT dysfunction in autoimmune disorders, which we will explore further. We also have novel data linking TOP1MT and mtDNA-mediated inflammation to toxicity caused by doxorubicin, a drug commonly used to treat cancer. Understanding how TOP1MT and inflammation mediate doxorubicin toxicity could lead to safer or alternative cancer treatments. Using a combination of cell and animal studies, our research will characterize how and why mtDNA is released in the context of TOP1MT dysfunction (Aim 1), interrogate the role of TOP1MT as a novel autoimmune disease gene (Aim 2), and explore TOP1MT as a doxorubicin susceptibility factor (Aim 3).
Programme
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
472640
Name
Shutt Timothy E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Genetics
Projecttitle
TOP1MT, mtDNA Release & Inflammation
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Genetics (Bridge Funding: Research Priorities)
Keyworddelim
Cgas-Sting; Doxorubicin; Inflammation; Mitochondrial; Mtdna; Top1mt; Topoisomerase
Abstract
Mitochondria, best known as the powerhouse of the cell, contain a small DNA genome, known as mtDNA that is essential for mitochondrial function. Recent work shows that when mtDNA escapes from mitochondria, it can activate immune signaling. While immune signaling can be protective in the context of infections, excess activation can be detrimental by leading to autoimmune disorders. The triggers initiating mtDNA escape and the mechanisms by which mtDNA exits mitochondria are not fully understood. We also do not have a full appreciation of the consequences of mtDNA release on human health. To begin to answer these questions, we will study the mtDNA regulator TOP1MT, which our novel findings show mediates mtDNA escape. With respect to human health, we have identified a candidate disease causing TOP1MT variant in a family with autoimmune disorders, and shown that this variant is linked to mtDNA release and immune activation. These findings support a role for TOP1MT dysfunction in autoimmune disorders, which we will explore further. We also have novel data linking TOP1MT and mtDNA-mediated inflammation to toxicity caused by doxorubicin, a drug commonly used to treat cancer. Understanding how TOP1MT and inflammation mediate doxorubicin toxicity could lead to safer or alternative cancer treatments. Using a combination of cell and animal studies, our research will characterize how and why mtDNA is released in the context of TOP1MT dysfunction (Aim 1), interrogate the role of TOP1MT as a novel autoimmune disease gene (Aim 2), and explore TOP1MT as a doxorubicin susceptibility factor (Aim 3).
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shutt, Timothy E; West, Andrew P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~